Key facts
- It has raised $5.9M; the latest was Accelerator/Incubator in May 2025.
- Notable investors include Bpifrance, La French Tech, UI Investissement, IRDI Capital Investissement, Sofilaro — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Neurinnov
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurinnov are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurinnov
Developer of active implantable medical devices (AIMD) intended to treat quadriplegic patients, whose muscles are paralyzed but stimulable. The company's device uses generic neurostimulation technology to stimulate a subset of nerve fibers within a nerve to obtain the therapeutic effect sought by minimizing undesirable effects, enabling quadriplegic patients to restore grip-in-hand functionality.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2018
- Employees
- 15
- Website
- neurinnov.com/
- Ownership
- Privately Held (backing)
Neurinnov doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurinnov shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurinnov in its N-PORT filings yet. We sweep new filings monthly.